Enhancement of the biological activity of BMP-2 by synthetic dextran derivatives

Journal of Biomedical Materials Research - Part A

Volumn 88, Issue 1, 2009, Pages 174-183

  Degat, Marie Christelle ^a,b   Dubreucq, Guy ^b   Meunier, Alain ^a   Dahri Correia, Latifa ^b   Sedel, Laurent ^a   Petite, Herve ^a   Logeart Avramoglou, Delphine ^a,b  

^a Paris university   (France)

^b Biodex ^*  (France)

Author keywords

Biological activity; BMP 2; DMCB; Heparin mimetic; Interaction between BMP 2 and DMCB

Indexed keywords

BIOMINERALIZATION; BIOPOLYMERS; BONE; CELL CULTURE; DEXTRAN; DIFFERENTIATION (CALCULUS); ELECTROPHORESIS; GLUCOSE; GROWTH (MATERIALS); PEPTIDES; POLYMERS; POLYSACCHARIDES;

BIOLOGICAL ACTIVITY; BMP-2; DMCB; HEPARIN MIMETIC; INTERACTION BETWEEN BMP-2 AND DMCB;

BIOACTIVITY;

ALKALINE PHOSPHATASE; BONE MORPHOGENETIC PROTEIN 2; DEXTRAN; DEXTRAN DERIVATIVE; POLYMER; POLYSACCHARIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOLOGICAL ACTIVITY; CALCIFICATION; CELL DIFFERENTIATION; COMPLEX FORMATION; CONTROLLED STUDY; CULTURE MEDIUM; ENZYME ACTIVITY; MOLECULAR INTERACTION; MOUSE; MYOBLAST; NONHUMAN; NUCLEOTIDE SEQUENCE; OSTEOBLAST; RAT;

ANIMALS; BONE MORPHOGENETIC PROTEIN 2; CALCIFICATION, PHYSIOLOGIC; CELL CULTURE TECHNIQUES; CELL DIFFERENTIATION; DEXTRANS; DRUG SYNERGISM; HEPARIN; HUMANS; MYOBLASTS; OSTEOBLASTS; POLYSACCHARIDES; RATS;

EID: 57449102955     PISSN: 15493296     EISSN: 15524965     Source Type: Journal    
DOI: 10.1002/jbm.a.31884     Document Type: Article

References (46)

1. Urist MR. Bone: Formation by autoinduction. Science 1965;150:893-899.
2. Balemans W, Van Hul W. Extracellular regulation of BMP signaling in vertebrates: A cocktail of modulators. Dev Biol 2002;250:231-250.
3. Wan M, Cao X. BMP signaling in skeletal development. Biochem Biophys Res Commun 2005;328:651-657.
4. Wozney JM. Overview of bone morphogenetic proteins. Spine 2002;27:S2-S8.
5. Cowan CM, Aalami OO, Shi YY, Chou YF, Mari C, Thomas R, Quarto N, Nacamuli RP, Contag CH, Wu B, Longaker MT. Bone morphogenetic protein 2 and retinoic acid accelerate in vivo bone formation, osteoclast recruitment, and bone turnover. Tissue Eng 2005;11:645-658.
6. Thies RS, Bauduy M, Ashton BA, Kurtzberg L, Wozney JM, Rosen V. Recombinant human bone morphogenetic protein-2 induces osteoblastic differentiation in W-20-17 stromal cells. Endocrinology 1992;130:1318-1324.
7. Yamaguchi A, Katagiri T, Ikeda T, Wozney JM, Rosen V, Wang EA, Kahn AJ, Suda T, Yoshiki S. Recombinant human bone morphogenetic protein-2 stimulates osteoblastic maturation and inhibits myogenic differentiation in vitro. J Cell Biol 1991;113:681-687.
8. Wang EA, Rosen V, D'Alessandro JS, Bauduy M, Cordes P, Harada T, Israel DI, Hewick RM, Kerns KM, LaPan P, Luxenberg D, McQuaid D, Moutsatsos I, Nove J, Wozney J. Recombinant human bone morphogenetic protein induces bone formation. Proc Natl Acad Sci USA 1990;87:2220-2224.
9. Wozney JM. The bone morphogenetic protein family and osteogenesis. Mol Reprod Dev 1992;32:160-167.
10. Termaat MF, Den Boer FC, Bakker FC, Patka P, Haarman HJ. Bone morphogenetic proteins. Development and clinical efficacy in the treatment of fractures and bone defects. J Bone Joint Surg Am 2005;87:1367-1378.
11. Harwood PJ, Giannoudis PV. Application of bone morphogenetic proteins in orthopaedic practice: Their efficacy and side effects. Expert Opin Drug Saf 2005;4:75-89.
12. Seeherman H, Wozney JM. Delivery of bone morphogenetic proteins for orthopedic tissue regeneration. Cytokine Growth Factor Rev 2005;16:329-345.
13. Canalis E, Economides AN, Gazzerro E. Bone morphogenetic proteins, their antagonists, and the skeleton. Endocr Rev 2003;24:218-235.
14. Ruppert R, Hoffmann E, Sebald W. Human bone morphogenetic protein 2 contains a heparin-binding site which modifies its biological activity. Eur J Biochem 1996;237:295-302.
15. Jiao X, Billings PC, O'Connell MP, Kaplan FS, Shore EM, Glaser DL. Heparan sulfate proteoglycans (HSPGS) modulate BMP2 osteogenic bioactivity in C2C12 cells. J Biol Chem 2007;282:1080-1086.
16. Irie A, Habuchi H, Kimata K, Sanai Y. Heparan sulfate is required for bone morphogenetic protein-7 signaling. Biochem Biophys Res Commun 2003;308:858-865.
17. Takada T, Katagiri T, Ifuku M, Morimura N, Kobayashi M, Hasegawa K, Ogamo A, Kamijo R. Sulfated polysaccharides enhance the biological activities of bone morphogenetic proteins. J Biol Chem 2003;278:43229-43235.
18. Zhao B, Katagiri T, Toyoda H, Takada T, Yanai T, Fukuda T, Chung UI, Koike T, Takaoka K, Kamijo R. Heparin potentiates the in vivo ectopic bone formation induced by bone morphogenetic protein-2. J Biol Chem 2006;281:23246-23253.
19. Logeart-Avramoglou D, Jozefonvicz J. Carboxymethyl benzylamide sulfonate dextrans (CMDBS), a family of biospecific polymers endowed with numerous biological properties: A review. J Biomed Mater Res 1999;48:578-590.
20. Tardieu M, Gamby C, Avramoglou T, Jozefonvicz J, Barritault D. Derivatized dextrans mimic heparin as stabilizers, potentiators, and protectors of acidic or basic FGF. J Cell Physiol 1992;150:194-203.
21. Bittoun P, Bagheri Yarmand R, Chaubet F, Crépin M, Jozefonvicz J, Fermandjian S. Effects of the binding of a dextran derivative on fibroblast growth factor 2: Secondary structure and receptor-binding studies. Biochem Pharmacol 1999;57:1399-1406.
22. Hamma-Kourbali Y, Vassy R, Starzec A, Le Meuth-Metzinger V, Oudar O, Bagheri-Yarmand R, Perret G, Crepin M. Vascular endothelial growth factor 165 (VEGF(165)) activities are inhibited by carboxymethyl benzylamide dextran that competes for heparin binding to VEGF(165) and VEGF(165). KDR Complexes. J Biol Chem 2001;276:39748-39754.
23. Bagheri Yarmand R, Kourbali Y, Morère JF, Jozefonvicz J, Crépin M. Inhibition of MCF-7ras tumor growth by carboxymethyl benzylamide dextran: Blockage of the paracrine effect and receptor binding of transforming growth factor beta1 and platelet-derived growth factor-BB. Cell Growth Differ 1998;9:497-504.
24. Carion O, Lefebvre J, Dubreucq G, Dahri-Correia L, Correia J, Melnyk O. Polysaccharide microarrays for polysaccharide-platelet-derived-growth-factor interaction studies. Chembiochem 2006;7:81726.
25. Logeart-Avramoglou D, Huynh R, Chaubet F, Sedel L, Meunier A. Interaction of specifically chemically modified dextrans with transforming growth factor beta1: Potentiation of its biological activity. Biochem Pharmacol 2002;63:129-137.
26. Mestries P, Alexakis C, Papy-Garcia D, Duchesnay A, Barritault D, Caruelle JP, Kern P. Specific RGTA increases collagen V expression by cultured aortic smooth muscle cells via activation and protection of transforming growth factor-beta1. Matrix Biol 2001;20:171-181.
27. Huynh R, Chaubet F, Jozefonvicz J. Anticoagulant properties of dextranmethylcarboxylate benzylamide sulfate (DMCBSu); a new generation of bioactive functionalized dextran. Carbohydr Res 2001;332:75-83.
28. Chaubet F, Huynh R, Dahri-Correia L, Correia J, Jozefowicz M, Jozefonvicz J. Dextran derivatives, preparation and medicinal applications. US Pat 6,646,120 B1 (2003).
29. Lee MK, Lander AD. Analysis of affinity and structural selectivity in the binding of proteins to glycosaminoglycans: Development of a sensitive electrophoretic approach. Proc Natl Acad Sci USA 1991;88:2768-2772.
30. Korchynskyi O, ten Dijke P. Identification and functional characterization of distinct critically important bone morphogenetic protein-specific response elements in the Id1 promoter. J Biol Chem 2002;277:4883-4891.
31. Logeart-Avramoglou D, Bourguignon M, Oudina K, Ten Dijke P, Petite H. An assay for the determination of biologically active bone morphogenetic proteins using cells transfected with an inhibitor of differentiation promoter-luciferase construct. Anal Biochem 2006;349:78-86.
32. McCaffrey TA, Falcone DJ, Du B. Transforming growth factor-beta 1 is a heparin-binding protein: Identification of putative heparin-binding regions and isolation of heparins with varying affinity for TGF- beta 1. J Cell Physiol 1992;152:430-440.
33. Katagiri T, Yamaguchi A, Komaki M, Abe E, Takahashi N, Ikeda T, Rosen V, Wozney JM, Fujisawa-Sehara A, Suda T. Bone morpihogenetic protein-2 converts the differentiation pathway of C2C12 myoblasts into the osteoblast lineage. J Cell Biol 1994;127:1755-1766.
34. Groeneveld EH, Burger EH. Bone morphogenetic proteins in human bone regeneration. Eur J Endocrinol 2000;142:9-21.
35. Ledoux D, Merciris D, Barritault D, Caruelle JP. Heparin-like dextran derivatives as well as glycosaminoglycans inhibit the enzymatic activity of human cathepsin G. FEBS Lett 2003;537:23-29.
36. Ohkawara B, Iemura S, ten Dijke P, Ueno N. Action range of BMP is defined by its N-terminal basic amino acid core. Curr Biol 2002;12:205-209.
37. Jasuja R, Allen BL, Pappano WN, Rapraeger AC, Greenspan DS. Cell-surface heparan sulfate proteoglycans potentiate chordin antagonism of bone morphogenetic protein signaling and are necessary for cellular uptake of chordin. J Biol Chem 2004;279:51289-51297.
38. Scheufler C, Sebald W, Hulsmeyer M. Crystal structure of human bone morphogenetic protein-2 at 2.7 A resolution. J Mol Biol 1999;287:103-115.
39. Blanquaert F, Saffar JL, Colombier ML, Carpentier G, Barritault D, Caruelle JP. Heparan-like molecules induce the repair of skull defects. Bone 1995;17:499-506.
40. Rouet V, Hamma-Kourbali Y, Petit E, Panagopoulou P, Katsoris P, Barritault D, Caruelle JP, Courty J. A synthetic glycosaminoglycan mimetic binds vascular endothelial growth factor and modulates angiogenesis. J Biol Chem 2005;280:32792-32800.
41. Bernfield M, Gotte M, Park PW, Reizes O, Fitzgerald ML, Lincecum J, Zako M. Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem 1999;68:729-777.
42. Jackson SM, Nakato H, Sugiura M, Jannuzi A, Oakes R, Kaluza V, Golden C, Selleck SB. Dally, a Drosophila glypican, controls cellular responses to the TGF-beta-related morphogen, Dpp. Development 1997;124:4113-4120.
43. Paine-Saunders S, Viviano BL, Zupicich J, Skarnes WC, Saunders S. Glypican-3 controls cellular responses to Bmp4 in limb patterning and skeletal development. Dev Biol 2000;225:179-187.
44. Grisaru S, Cano-Gauci D, Tee J, Filmus J, Rosenblum ND. Glypican-3 modulates BMP- and FGF-mediated effects during renal branching morphogenesis. Dev Biol 2001;231:31-46.
45. Zimmerman LB, De Jesus-Escobar JM, Harland RM. The Spemann organizer signal noggin binds and inactivates bone morphogenetic protein 4. Cell 1996;86:599-606.
46. Cho KW, Blitz IL. BMPs, Smads and metalloproteases: Extracellular and intracellular modes of negative regulation. Curr Opin Genet Dev 1998;8:443-449.